Quidel ($QDEL) has received the CE mark for its first molecular diagnostic test, the Influenza A+B real-time RT-PCR assay. The CE mark allows for the launch of the open box molecular platform in advance of the forthcoming influenza season in Europe. The product is not for sale in the U.S. at this time. Quidel release